Rocket Lab TodayRKLBRocket Lab$27.85 +1.43 (+5.41%) 52-Week Range$4.20▼$33.34Price Target$28.10Add to WatchlistAerospace and defense corporation Rocket Lab USA NASDAQ: RKLB recently received a significant analyst boost when Cantor Fitzgerald increased its target price for the space company to a street-high $35. The upgrade follows several recent positive initiatives by the company, as it continues to impress with its strategic advancements, upcoming pipeline, and proven track record.  The company's ongoing ...

从政策红利到产业实践，中国金融开放正从量的扩容迈向质的深化。6月18日，在2025陆家嘴论坛上， 金融监管总局局长李云泽为外资机构勾勒出政策优化、科技金融与财富管理等多维度的发展蓝图。他透 露，金融监管总局正在大力推进金融资产投资公司股权投资、科技企业并购贷款等试点，不断探索科技 金融发展新路径；支持外资机构在理财投资、资产配置、保险规划等领域加大布局。外资机构迎来深耕 细分领域、共享发展红利的战略机遇期。 政策环境持续优化升级 "无论国际风云如何变幻，中国金融业扩大高水平开放的决心不会改变，构建互利共赢金融发展格局的 决心不会改变，推动建立更加包容的国际金融体系的决心不会改变。"在2025陆家嘴论坛上，李云泽 以"三大决心"锚定中国金融业高水平开放方向。 在政策层面，他强调，近年来，金融监管总局着力健全规则、规制、管理、标准体系，完善准入前国民 待遇加负面清单管理模式，银行保险领域的限制性措施已经基本取消。下一步，将大力复制推广自贸 区、自贸港扩大制度型开放的经验做法，支持外资机构参与更多金融业务试点。对标国际高标准经贸协 议中金融领域相关规则，探索在更宽领域、更大幅度上加大开放力度。 同日，《关于支持上海 ...

Core Insights - Satellogic, Inc. has been selected as the technology partner for the Malaysian High-Resolution Earth Observation Satellite Project (MHREOSP) in collaboration with Uzma Berhad [1][3] - The project aims to design, develop, assemble, integrate, and test a high-resolution satellite with a resolution of 50cm across all spectral bands, enhancing Malaysia's geospatial intelligence capabilities [2][3] - This partnership aligns with Malaysia's Space Exploration 2030 Action Plan and aims to nurture local talent through knowledge sharing and technology transfer [3][4] Company Overview - Founded in 2010, Satellogic is a vertically integrated geospatial company focused on providing high-resolution Earth observation data [4][5] - The company aims to democratize access to geospatial data to address global challenges such as climate change, energy supply, and food security [5][6] - Satellogic has a proven track record in satellite technology, having successfully deployed over 50 NewSat satellites [2][6] Strategic Importance - The collaboration strengthens Satellogic's presence in Asia and supports its mission to democratize access to advanced space technology [3][4] - The partnership is expected to enhance national sovereignty through proprietary space access and contribute to Malaysia's long-term infrastructure and environmental sustainability [4][3] - The project will involve significant local participation, fostering homegrown capacity development in satellite technology [2][3]

RT Tesla Owners Silicon Valley (@teslaownersSV)“My boss Elon Musk founded this company @SpaceX in 2002 with the purpose of building rockets and spaceships to enable people to live on other planets”Gwynne Shotwell https://t.co/lDHNTb0HIU ...

“The goal of @SpaceX is to extend the life sustainability to another planet and Mars is the only option.”Elon Musk https://t.co/WQpoEqdSDm ...

“My boss Elon Musk founded this company @SpaceX in 2002 with the purpose of building rockets and spaceships to enable people to live on other planets”Gwynne Shotwell https://t.co/lDHNTb0HIU ...

We are back with an update to Josh's best stocks in the market. I'll send it to you for that. What do you want to talk about.Uh I think obviously the thing that we have to talk about is the defense sector. We've got a bunch of these names on the best stocks list. We've been talking about them and last week of course they broke out on the heels of the conflration in the Middle East getting uh hotter.We talked about Axon and we talked about RTX on May 19th. from that date. RTX is up about 8 and a half%, Axon' ...

The Starship is going to allow access to Mars.It’ll push humanity to its furthest point and open the door to go/live on another planet. https://t.co/e0ChKatmAW ...

Core Viewpoint - ABB has entered into a Memorandum of Understanding (MoU) with HEMERIA to jointly explore solutions for space situational awareness (SSA), aiming to enhance global space traffic management and ensure optimal performance and reliability of satellite systems [1][4][6] Group 1: Collaboration Details - The collaboration will focus on integrating ABB's high-precision multispectral payloads with HEMERIA's satellite platforms [2][6] - The partnership aims to advance the responsible and secure use of space, improving global space surveillance capabilities [4][6] Group 2: Technological Capabilities - ABB's payloads are designed to detect and track objects in complex environments, facilitating real-time data collection for satellite operators and space agencies [3][6] - HEMERIA's satellite platforms provide agility, stability, and resilience for various space missions, ensuring high performance [3][6] Group 3: Industry Context - The increasing number of satellites and space missions has made space situational awareness a global priority to prevent collisions and manage orbital debris [4]

Core Insights - Clearside Biomedical is advancing the delivery of therapies to the back of the eye through its proprietary suprachoroidal space (SCS) injection platform, which will be highlighted at the upcoming Clinical Trials at the Summit (CTS) Meeting [1][2] Company Overview - Clearside Biomedical, Inc. is a biopharmaceutical company focused on improving patient outcomes by utilizing its SCS injection platform for targeted delivery of therapies to treat sight-threatening eye diseases [7] - The company’s lead product, CLS-AX (axitinib injectable suspension), is in development for neovascular age-related macular degeneration (wet AMD) and is preparing for a Phase 3 program [7] Technology and Innovation - The SCS Microinjector is a patented device that allows for in-office, repeatable, non-surgical procedures to deliver a variety of therapies directly to the macula, retina, or choroid [5][7] - CLS-AX is designed as a longer-acting therapy that achieves pan-VEGF blockade, potentially offering advantages over existing anti-VEGF therapies by targeting different levels of the angiogenesis cascade [4][5] Clinical Development - The company is showcasing multiple presentations related to its SCS delivery platform and its development partners at the CTS Meeting, including updates on CLS-AX for neovascular AMD and ABBV-RGX-314 for diabetic retinopathy [3][4] - Early clinical trials for CLS-AX have shown it to be well tolerated with a positive safety profile, indicating its potential for prolonged duration and targeted delivery [4]